These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10981248)

  • 21. Selegiline and rasagiline: twins or distant cousins?
    Knudsen Gerber DS
    Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
    Turkka J; Suominen K; Tolonen U; Sotaniemi K; Myllylä VV
    Neurology; 1997 Mar; 48(3):662-7. PubMed ID: 9065544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal selegiline and intravenous cocaine: safety and interactions.
    Houtsmuller EJ; Notes LD; Newton T; van Sluis N; Chiang N; Elkashef A; Bigelow GE
    Psychopharmacology (Berl); 2004 Feb; 172(1):31-40. PubMed ID: 14605792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline.
    Haberny KA; Walsh SL; Ginn DH; Wilkins JN; Garner JE; Setoda D; Bigelow GE
    Drug Alcohol Depend; 1995 Jul; 39(1):55-62. PubMed ID: 7587975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
    Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
    Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
    [No Abstract]   [Full Text] [Related]  

  • 31. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline.
    Riley DE
    Clin Neuropharmacol; 2002; 25(4):234-7. PubMed ID: 12151912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selegiline transdermal system Somerset.
    Mahmood I
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline in ADHD adults: plasma monoamines and monoamine metabolites.
    Ernst M; Liebenauer LL; Tebeka D; Jons PH; Eisenhofer G; Murphy DL; Zametkin AJ
    Neuropsychopharmacology; 1997 Apr; 16(4):276-84. PubMed ID: 9094145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoamine oxidase inhibitor efficacy in depression and the "cheese effect".
    Sandler M
    Psychol Med; 1981 Aug; 11(3):455-8. PubMed ID: 6791195
    [No Abstract]   [Full Text] [Related]  

  • 35. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
    Li XM; Juorio AV; Paterson IA; Boulton AA
    J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
    [No Abstract]   [Full Text] [Related]  

  • 38. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoamine oxidase inhibitors and cardiac anesthesia revisited.
    Noorily SH; Hantler CB; Sako EY
    South Med J; 1997 Aug; 90(8):836-8. PubMed ID: 9258314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.